Jubilant Pharmova Limited has announced that the U.S. Food and Drug Administration (USFDA) has concluded its inspection of the Jubilant HollisterStier LLC CMO facility in Spokane, Washington. The facility has been classified as ‘Voluntary Action Indicated’ (VAI). This classification follows an inspection conducted from June 8 to June 17, 2026.
USFDA Inspection Update
Jubilant Pharmova Limited shared an update regarding the U.S. Food and Drug Administration’s (USFDA) review of its subsidiary Jubilant HollisterStier LLC’s contract manufacturing organization (CMO) facility located in Spokane, Washington, USA. The inspection took place between June 8, 2026, and June 17, 2026.
Facility Classification
Following the conclusion of the inspection and the review of the Establishment Inspection Report (EIR), the USFDA has classified the Spokane facility as ‘Voluntary Action Indicated’ (VAI). This classification is a significant outcome of the regulatory review process for the facility, which is a key operational site for the company’s sterile injectables manufacturing.
Subsidiary Structure
Jubilant HollisterStier LLC operates as a subsidiary of Jubilant Pharma Holding Inc., which is itself a wholly-owned subsidiary of Jubilant Pharma Limited, Singapore. Jubilant Pharmova Limited is the ultimate parent company.
Source: BSE
